Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Recent advances in defining the genetic mechanisms of disease causation and modification in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some extreme disease manifestations and other phenotypic variability. Studies of the ADPKD proteins, polycystin-1 and -2, and the development and characterization of animal models that better mimic the human disease, have also helped us to understand pathogenesis and facilitated treatment evaluation. In addition, an improved understanding of aberrant downstream pathways in ADPKD, such as proliferation/secretion-related signaling, energy metabolism, and activated macrophages, in which cAMP and calcium changes may play a role, is leading to the identification of therapeutic targets. Finally, results from recent and ongoing preclinical and clinical trials are greatly improving the prospects for available, effective ADPKD treatments.

Original languageEnglish (US)
Pages (from-to)2315-2324
Number of pages10
JournalJournal of Clinical Investigation
Volume124
Issue number6
DOIs
StatePublished - Jun 2 2014

Fingerprint

Autosomal Dominant Polycystic Kidney
Inborn Genetic Diseases
Causality
Energy Metabolism
Animal Models
Macrophages
Clinical Trials
Calcium
Proteins
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. / Harris, Peter C; Torres, Vicente.

In: Journal of Clinical Investigation, Vol. 124, No. 6, 02.06.2014, p. 2315-2324.

Research output: Contribution to journalArticle

@article{222835a0a38748c3923863495ddb89e2,
title = "Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease",
abstract = "Recent advances in defining the genetic mechanisms of disease causation and modification in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some extreme disease manifestations and other phenotypic variability. Studies of the ADPKD proteins, polycystin-1 and -2, and the development and characterization of animal models that better mimic the human disease, have also helped us to understand pathogenesis and facilitated treatment evaluation. In addition, an improved understanding of aberrant downstream pathways in ADPKD, such as proliferation/secretion-related signaling, energy metabolism, and activated macrophages, in which cAMP and calcium changes may play a role, is leading to the identification of therapeutic targets. Finally, results from recent and ongoing preclinical and clinical trials are greatly improving the prospects for available, effective ADPKD treatments.",
author = "Harris, {Peter C} and Vicente Torres",
year = "2014",
month = "6",
day = "2",
doi = "10.1172/JCI72272",
language = "English (US)",
volume = "124",
pages = "2315--2324",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease

AU - Harris, Peter C

AU - Torres, Vicente

PY - 2014/6/2

Y1 - 2014/6/2

N2 - Recent advances in defining the genetic mechanisms of disease causation and modification in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some extreme disease manifestations and other phenotypic variability. Studies of the ADPKD proteins, polycystin-1 and -2, and the development and characterization of animal models that better mimic the human disease, have also helped us to understand pathogenesis and facilitated treatment evaluation. In addition, an improved understanding of aberrant downstream pathways in ADPKD, such as proliferation/secretion-related signaling, energy metabolism, and activated macrophages, in which cAMP and calcium changes may play a role, is leading to the identification of therapeutic targets. Finally, results from recent and ongoing preclinical and clinical trials are greatly improving the prospects for available, effective ADPKD treatments.

AB - Recent advances in defining the genetic mechanisms of disease causation and modification in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some extreme disease manifestations and other phenotypic variability. Studies of the ADPKD proteins, polycystin-1 and -2, and the development and characterization of animal models that better mimic the human disease, have also helped us to understand pathogenesis and facilitated treatment evaluation. In addition, an improved understanding of aberrant downstream pathways in ADPKD, such as proliferation/secretion-related signaling, energy metabolism, and activated macrophages, in which cAMP and calcium changes may play a role, is leading to the identification of therapeutic targets. Finally, results from recent and ongoing preclinical and clinical trials are greatly improving the prospects for available, effective ADPKD treatments.

UR - http://www.scopus.com/inward/record.url?scp=84902188257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902188257&partnerID=8YFLogxK

U2 - 10.1172/JCI72272

DO - 10.1172/JCI72272

M3 - Article

C2 - 24892705

AN - SCOPUS:84902188257

VL - 124

SP - 2315

EP - 2324

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -